These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 27269057)

  • 61. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
    Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L
    Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.
    Harris SL; Donald RG; Hawkins JC; Tan C; O'Neill R; McNeil LK; Perez JL; Anderson AS; Jansen KU; Jones TR
    Pediatr Infect Dis J; 2017 Feb; 36(2):216-223. PubMed ID: 27846061
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.
    Moe GR; Zuno-Mitchell P; Hammond SN; Granoff DM
    Infect Immun; 2002 Nov; 70(11):6021-31. PubMed ID: 12379678
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A putative amino acid ABC transporter substrate-binding protein, NMB1612, from Neisseria meningitidis, induces murine bactericidal antibodies against meningococci expressing heterologous NMB1612 proteins.
    Hung MC; Humbert MV; Laver JR; Phillips R; Heckels JE; Christodoulides M
    Vaccine; 2015 Aug; 33(36):4486-94. PubMed ID: 26207592
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.
    Lee HJ; Choe YJ; Hong YJ; Kim KH; Park SE; Kim YK; Oh CE; Lee H; Song H; Bock H; Casula D; Bhusal C; Arora AK
    Vaccine; 2016 Feb; 34(9):1180-6. PubMed ID: 26826544
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine.
    Green LR; Eiden J; Hao L; Jones T; Perez J; McNeil LK; Jansen KU; Anderson AS
    Methods Mol Biol; 2016; 1403():445-69. PubMed ID: 27076147
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Kaaijk P; van Straaten I; van de Waterbeemd B; Boot EP; Levels LM; van Dijken HH; van den Dobbelsteen GP
    Vaccine; 2013 Feb; 31(7):1065-71. PubMed ID: 23273968
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp).
    Abad R; García-Amil C; Navarro C; Martín E; Martín-Díaz A; Vázquez JA
    J Infect; 2021 Apr; 82(4):37-44. PubMed ID: 33610688
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Understanding immunogenicity assessments for meningococcal serogroup B vaccines.
    Balmer P; Beeslaar J; Findlow J; Srivastava A
    Postgrad Med; 2020 Mar; 132(2):184-191. PubMed ID: 32124678
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.
    Marshall HS; Richmond PC; Nissen MD; Wouters A; Baber J; Jiang Q; Anderson AS; Jones TR; Harris SL; Jansen KU; Perez JL
    Vaccine; 2013 Mar; 31(12):1569-75. PubMed ID: 23352429
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.
    Giuntini S; Lujan E; Gibani MM; Dold C; Rollier CS; Pollard AJ; Granoff DM
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847367
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination.
    Silva Junior FC; Gioia CA; Oliveira JM; Cruz SC; Frasch CE; Milagres LG
    Scand J Immunol; 2007 Jan; 65(1):1-7. PubMed ID: 17212760
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
    Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A
    Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice.
    Rossi R; Granoff DM; Beernink PT
    Vaccine; 2013 Nov; 31(46):5451-7. PubMed ID: 24035433
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
    Vesikari T; Østergaard L; Diez-Domingo J; Wysocki J; Flodmark CE; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Crowther G; Perez JL
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):152-60. PubMed ID: 26407272
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial.
    Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ
    mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1.
    Brunelli B; Del Tordello E; Palumbo E; Biolchi A; Bambini S; Comanducci M; Muzzi A; Pizza M; Rappuoli R; Donnelly JJ; Giuliani MM; Serruto D
    Vaccine; 2011 Jan; 29(5):1072-81. PubMed ID: 21130753
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.
    Fazio C; Biolchi A; Neri A; Tomei S; Vacca P; Ambrosio L; Palmieri A; Mori E; La Gaetana R; Pizza M; Giuliani MM; Serino L; Stefanelli P
    Hum Vaccin Immunother; 2021 Jul; 17(7):2225-2231. PubMed ID: 33522380
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870.
    Koeberling O; Welsch JA; Granoff DM
    Vaccine; 2007 Feb; 25(10):1912-20. PubMed ID: 16677743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.